VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

FPV-LT vaccine
Vaccine Information
  • Vaccine Name: FPV-LT vaccine
  • Target Pathogen: infectious laryngotracheitis virus
  • Vaccine Ontology ID: VO_0004624
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Chicken
  • Vector:
  • Preparation: Viral vector vaccines using fowl poxvirus (FPV) and herpesvirus of turkey (HVT) as vectors and carrying infectious laryngotracheitis virus (ILTV) genes (Vagnozzi et al., 2012).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Chicken Response

  • Vaccination Protocol: Live-attenuated ILT vaccines were administered as a full dose, and the recombinant vectored vaccines were administered as a half dose to mimic broiler industry practices. The viral vector vaccines were administered in ovo and subcutaneously at hatch while the live-attenuated vaccines, CEO and TCO, were administered via eye drop at 14 days of age (Vagnozzi et al., 2012).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: All chickens were weighed before challenge. With the exception of the NVx-NCh group, all chickens were challenged at 35 days of age with the virulent ILTV field isolate 63140 administered in a total volume of 200 µl, 100 µl intratracheally and 50 µl via eye drop per eye (Vagnozzi et al., 2012).
  • Efficacy: The FPV-LT vaccine mitigated clinical signs more effectively when administered subcutaneously than in ovo (Vagnozzi et al., 2012).
References
Vagnozzi et al., 2012: Vagnozzi A, Zavala G, Riblet SM, Mundt A, GarcĂ­a M. Protection induced by commercially available live-attenuated and recombinant viral vector vaccines against infectious laryngotracheitis virus in broiler chickens. Avian pathology : journal of the W.V.P.A. 2012; 41(1); 21-31. [PubMed: 22845318].